Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04223167
Other study ID # 2017/1211
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 20, 2018
Est. completion date May 14, 2019

Study information

Verified date January 2020
Source Aydin Adnan Menderes University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The consumption of energy drinks has significantly increased in recent years but their adverse effects are not yet efficiently known. The objective of the study is to determine the acute effects of energy drink on habitual and non-habitual caffeine consumers and if caffeine consumption habit causes a difference on the hemodynamic and electrophysiologic parameters.

This study was conducted on 48 students selected from Aydın Adnan Menderes University. Four main groups were determined according to the results of the application acceptance survey. Blood pressure, electrocardiogram, breath rate, haemoglobin oxygen saturation and bioelectrical impedance analysis were measured before consuming the drinks. After consuming the drinks, measurements were repeated at 30 minutes and 60 minutes. In addition to this, Participant's Situation Anxiety Scale was applied.


Description:

In this study, it is aimed to determine the acute effects of energy drink on habitual and non-habitual caffeine consumers and if caffeine consumption habit causes a difference on the hemodynamic and electrophysiologic parameters. In this respect, the complicated human body's reactions to these beverages will be examined in more detail.

Materials and methods Participants Forty eight participants (16 female, 32 male) aged 18-24 were selected from the students which are in the first year of various faculties of Aydın Adnan Menderes University. The individuals were identified by collecting the age, weight, height, BMI, caffeine and energy drink consumption habit information by applicant acceptance questionnaire. According to the results of applicant acceptance questionnaire, those with a body mass index greater than 30 kg/m2, a systemic disease, current alcoholism and smokers were not included in the study. Also, the participants who has previous adverse reactions to energy drinks were excluded to prevent undesired reactions associated with this condition. Based on the applicant acceptance questionnaire 12 subjects were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and named as energy drink 2 (ED2) group, 12 subjects were high-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and named as energy drink 3 (ED3) group, while 24 subjects were caffeine naive (energy drink 1 (ED1) (n=12) and Control (n=12)) . This study conforms to the Declaration of Helsinki and was approved by the Institutional Medical Ethics Committee of Adnan Menderes University (Protocol number: 2017/1211).

Experimental protocol All experiments were performed in a quiet and isolated room from external factors with room temperature of about 20°C and relative humidity between %40 and 60. All participants were advised to avoid alcohol and caffeine containing foods for at least 72 h prior to the test and to come with an overnight (12 h) fasting.

Blood pressure, electrocardiogram, breath rate, haemoglobin oxygen saturation (HOS) and BIA measurements were performed from the participants before the consumption of drinks. After the measurements ED1, ED2 and ED3 groups consumed 473 ml of Red Bull energy drink containing 151.36 mg caffeine and control group consumed the same amount of water within 5 minutes. The measurements were performed again in 30 minutes and 60 minutes. Also, state-trait anxiety inventory test (STAI) was used to assess the physiological stress of the participants.

Blood Pressure Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured indirectly by using a stethoscope (Littman Classic II, Saint Paul, USA) and aneroid sphygmomanometer (Welch Allyn Tycos, New York, USA) on each participant left arm in sitting position.

Electrocardiography (ECG) After a 5 min resting in the sitting position ECG recordings were obtained from all the individuals for 5 min in rest. Disposable Ag-AgCl electrodes were placed following the Einthoven triangle configuration. ECG measurement was performed with sampling frequency 200 Hz using ECG100C unit and BIOPAC Acqknowledge acquisition software (Biopac System Inc., Santa Barbara, CA) connected to a personal computer. PR interval, QRS complex and QTc interval values were determined from ECG recordings of the participants. QTc was calculated by Bazett's formula (QTc=QT/RR). Their normal range values are 120-200 ms, normal<140 ms and normal < 400 ms, respectively.

For acquiring the heart rate variability (HRV) time series, Pan and Thompkins algorithm was used. R peaks were detected and R-R intervals are defined. The time duration between two consecutive R peaks is termed as RR interval (tRR). The sample size of the HRV time series is 400. The heart rate (HR) is determined as:

HR=60/t_RR State-trait Anxiety Inventory (STAI) It is a test developed to determine the psychological stress during the study. STAI is defined as state and trait anxiety scale. This test is composed of two parts (40 questions). State Anxiety scale consisting of the first 20 questions was used to obtain information about the acute anxiety state of participants at the time of the study. Each question is evaluated using an ordinal scale (not at all=1, somewhat=2, moderately=3, very much=4). The total score is obtained as the sum of each answer value and gives information about the anxiety state of the participant. A total score of 50 or more is considered as positive pathological anxiety.

Haemoglobin Oxygen Saturation (HOS) HOS was measured by using a fingertip pulse oximeter on the second left finger for 1 min.

Breath Rate Breath rate measurements were taken from the participants by counting the breaths for one minute with the use of a stethoscope (Littman Classic II, Saint Paul, USA).

Bioelectrical Impedance Analysis (BIA) BIA measurements were taken by using In Body 720 before the consumption of the drinks and at 60th minute after the consumption. Each participant was asked to stand on the body composition analyzer after undressing their clothes. In Body 720 has an eight-point tactile electrode system that separately measures the impedance of the arms, trunk and legs. It measures directly the amount of the intracellular water (ICW), extracellular water (ECW), body fat percentage (PBF), body mass index (BMI) and body metabolism rate (BMR).

Statistical analysis Statistical analysis of the data was performed by using SPSS Statistics for Windows, Version 14.0. (SPSS Inc., Chicago, Illinois, USA). For comparing the groups first of all Shapiro-Wilk (SW) normality test was applied to determine the normality of the distribution. If the result of (SW) normality test was bigger than 0.05 the data were normally distributed and were analysed by using one-way analysis of variance (ANOVA) with Bonferroni post-test but if the result was less than 0.05 the data were not normally distributed and were analysed by using Kruskal-Wallis non-parametric test. Repeated ANOVA test was used for the comparison of different measurement time data of the same group. Descriptive statistics were presented as mean ± standard error of the mean (SEM). A p-value of less than 0.05 was considered to indicate statistical significance.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date May 14, 2019
Est. primary completion date May 14, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 24 Years
Eligibility Inclusion Criteria:

- Healthy volunteers between ages 18-24 years

Exclusion Criteria:

- body mass index greater than 30 kg/m2

- a systemic disease

- current alcoholism

- smokers

- the participants who has previous adverse reactions to energy drinks

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Red Bull Energy Drink
473 ml Reb Bull Energy Drink
Water
473 ml Water

Locations

Country Name City State
Turkey Aydin Adnan Menderes University Aydin

Sponsors (1)

Lead Sponsor Collaborator
Aydin Adnan Menderes University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in blood pressure from baseline At baseline and 60 minutes post energy drink and placebo consumption
Primary Change in heart rate from baseline At baseline and 60 minutes post energy drink and placebo consumption
Secondary Change in QTc interval from baseline At baseline and 60 minutes post energy drink and placebo consumption
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1